EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to nine new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The company, focused on developing therapeutics for serious retinal diseases, issued options to purchase up to 106,600 shares of common stock on August 15, 2024. These grants, approved by the Compensation Committee, have an exercise price of $8.20 per share, matching the closing price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha concesso opzioni azionarie non statutarie a nove nuovi dipendenti come premio di inducimento al di fuori del suo Piano di Incentivi a Lungo Termine 2023. L'azienda, focalizzata sullo sviluppo di terapie per gravi malattie retiniche, ha emesso opzioni per l'acquisto di fino a 106.600 azioni di azioni ordinarie il 15 agosto 2024. Questi riconoscimenti, approvati dal Comitato per la Retribuzione, hanno un prezzo di esercizio di $8,20 per azione, corrispondente al prezzo di chiusura della data di concessione. Le opzioni hanno un termine di dieci anni e maturano in quattro anni, con il 25% che matura al primo anniversario e il resto in rate mensili uguali nei tre anni successivi, a condizione di un'occupazione continuativa.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha otorgado opciones sobre acciones no estatutarias a nueve nuevos empleados como premios de inducción fuera de su Plan de Incentivos a Largo Plazo 2023. La empresa, centrada en el desarrollo de terapias para enfermedades retinianas graves, emitió opciones para comprar hasta 106,600 acciones ordinarias el 15 de agosto de 2024. Estas concesiones, aprobadas por el Comité de Compensación, tienen un precio de ejercicio de $8.20 por acción, igual al precio de cierre en la fecha de concesión. Las opciones tienen un plazo de diez años y se consolidan en cuatro años, con un 25% consolidándose en el primer aniversario y el resto en cuotas mensuales iguales durante los tres años siguientes, sujeto a empleo continuo.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 새로운 직원 9명에게 2023년 장기 인센티브 계획 외부에서 유인 보상으로 비법적 주식 옵션을 부여했습니다. 심각한 망막 질환에 대한 치료제를 개발하는 데 주력하는 이 회사는 2024년 8월 15일에 106,600주의 보통주 매입 옵션을 발행했습니다. 보상위원회에서 승인된 이 보상은 부여일의 종가와 같은 주당 $8.20의 행사 가격을 가집니다. 옵션의 유효 기간은 10년이며, 4년에 걸쳐 발생합니다. 첫 번째 기념일에 25%가 발생하고 나머지는 계속 고용되는 조건 하에 이후 3년에 걸쳐 월별 균등 할부로 지급됩니다.
EyePoint Pharmaceuticals (NASDAQ : EYPT) a accordé des options sur actions non statutaires à neuf nouveaux employés en tant que récompenses incitatives en dehors de son Plan de primes à long terme 2023. L'entreprise, axée sur le développement de thérapies pour des maladies rétiniennes graves, a émis des options d'achat jusqu'à 106 600 actions ordinaires le 15 août 2024. Ces attributions, approuvées par le Comité de rémunération, ont un prix d'exercice de 8,20 $ par action, correspondant au prix de clôture à la date d'attribution. Les options ont une durée de dix ans et s'acquièrent sur quatre ans, avec 25 % qui s'acquièrent lors du premier anniversaire et le reste en versements mensuels égaux au cours des trois années suivantes, sous réserve d'un emploi continu.
EyePoint Pharmaceuticals (NASDAQ: EYPT) hat nicht-statutäre Aktienoptionen an neun neue Mitarbeiter als Anreizpreise außerhalb seines langfristigen Anreizplans 2023 gewährt. Das Unternehmen, das sich auf die Entwicklung von Therapeutika für schwere Netzhauterkrankungen konzentriert, gab am 15. August 2024 Optionen zum Kauf von bis zu 106.600 Aktien aus. Diese Zuwendungen, die vom Vergütungsausschuss genehmigt wurden, haben einen Ausübungspreis von 8,20 USD pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht. Die Optionen haben eine Laufzeit von zehn Jahren und werden über vier Jahre fällig, wobei 25% am ersten Jahrestag fällig werden und der Rest in gleichen monatlichen Raten über die folgenden drei Jahre, vorbehaltlich einer fortdauernden Beschäftigung.
- Attraction of new talent with stock options as inducement
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
WATERTOWN, Mass., Aug. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 106,600 shares of EyePoint Pharmaceuticals common stock to nine new employees. The stock options were granted on August 15, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and diabetic macular edema (DME). EyePoint expects to randomize patients for inclusion in pivotal Phase 3 clinical trials in wet AMD in 2024.
Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint Pharmaceuticals:
Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
How many new employees received stock options from EyePoint Pharmaceuticals (EYPT) on August 15, 2024?
What is the exercise price of the stock options granted by EyePoint Pharmaceuticals (EYPT) on August 15, 2024?
What is the vesting schedule for the stock options granted by EyePoint Pharmaceuticals (EYPT)?
How many shares of EyePoint Pharmaceuticals (EYPT) common stock can be purchased with the granted stock options?
